CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 24 target
Drug / intervention
Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06919081
NCT06919081Phase 2RecruitingMonitorUpdated 5mo ago · Completion was 3mo ago
Slow Enrollment
Monitor
CompareCT.gov

Phase II Study of the Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

University of Illinois at Chicago·interventional·Posted Apr 9, 2025·Updated Jan 29, 2026

In Brief

A Phase 2 clinical trial evaluating Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome and Vehicle Control for Persistent Corneal Epithelial Defect and Corneal Epithelial Disorders. Currently recruiting, targeting 24 participants across 1 site.

Signals

Enrolling slower than its timeline implies

Detailed Summary

In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPersistent Corneal Epithelial Defect, Corneal Epithelial Disorders
CountriesUnited States
CollaboratorsNational Eye Institute (NEI), National Institutes of Health (NIH)

Timeline

Phase 2RecruitingOverdue
2026
First PostedApr 9, 2025
Enrollment StartAug 1, 2025
Primary CompletionMar 15, 2026
Study CompletionJun 15, 2026
TodayJul 1, 2026
Enrollment to primary: 7 monthsPosted 1.2 years ago

Interventions

Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretomedrug

Eye Drops

Vehicle Controlother

Eye Drops